After transformation, survival rates varied by original cancer type, with the poorest prognosis for those transformed from CLL/SLL and from LPL/WM.

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not ...

Knight Therapeutics Inc., (TSX: GUD) ('Knight') a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a ...

The National Institute for Health and Care Excellence (NICE) has recommended BeOne Medicines’ targeted cancer drug Brukinsa (zanubrutinib) to treat certain cases of mantle cell lymphoma (MCL).

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and ...

Imugene announces phase 1b trial evaluating azer-cel in patients with relapsed/refractory diffuse large B-cell lymphoma: Sydney Wednesday, July 16, 2025, 15:30 Hrs [IST] Imugene L ...

To combat the onslaught of litigation, Bayer has been pushing legislation in nine states, that would shield the company from ...

Pemivibart was well tolerated and prophylactic against COVID-19 infection among adult patients with significant immunocompromising conditions.

Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will ...